Alternations of VEGF blood levels in pulmonary sarcoidosis
23 February 2017 (online)
Little is known about potential predictive factors of pulmonary sarcoidosis progression. Therefore, the aim of our study was to assess blood markers such as vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) involved primarily in angiogenesis and fibrosis.
In a total of 77 patients with pulmonary sarcoidosis in stages I-III with or without oral cortisone therapy blood levels of VEGF, PDGF and FGF were measured by an enzyme-linked immunosorbent assay (ELISA). Active sarcoidosis was defined as the increase in blood concentrations of sarcoidosis markers such as angiotensin converting enzyme (ACE) and/or soluble interleukin 2 receptor (sIL-2R) above the normal range. Cut-off value for a relevantly decreased lung diffusing capacity amounted to 65% of a predicted value.
VEGF was significantly increased in the following groups of patients: sarcoidosis in stages III (101.8 ± 13.2 vs. stages I+II: 73.7 ± 3.5pg/ml), sarcoidosis with oral cortisone therapy (89.3 ± 7.4 vs. without oral cortisone therapy: 71.1 ± 4.5pg/ml), active sarcoidosis (92.1 ± 8.2 vs. non-active sarcoidosis: 72.0 ± 4.0pg/ml) and sarcoidosis with a relevantly decreased lung diffusing capacity (96.6 ± 12.6 vs. no relevant reduction of lung diffusing capacity: 76.1 ± 4.1pg/ml). Levels of PDGF and FGF were similar between the compared groups.
Advanced stages of pulmonary sarcoidosis, cortisone therapy, elevated sarcoidosis markers in blood and reduced lung diffusing capacity are associated with increased VEGF blood levels.